Hereditary Amyloidosis Treatment Market Report 2026: Analyst-Verified Data & Forecast

Hereditary Amyloidosis Treatment by Type (/> Drug Treatment, Surgical Treatment), by Application (/> Hospitals, Clinics, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $0.9 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $0.9 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Hereditary Amyloidosis Treatment Market Overview

The Hereditary Amyloidosis Treatment market (synonyms: hATTR therapy market, familial amyloidosis drug market) spans RNAi therapeutics, TTR stabilizers, and gene-silencing oligonucleotides aimed at halting or reversing misfolded-transthyretin accumulation. With a 2025 Hereditary Amyloidosis Treatment market size estimated at USD 2.8 billion, the sector is moving from orphan-price-protected biologics toward competitively tendered oral and injectable regimens, creating a complex growth outlook for manufacturers and payers alike.

Loading chart…

The market forecast points to a 9–11% CAGR through 2033, propelled by label expansions of patisiran and vutrisiran into cardiomyopathy, a broadening newborn-sequencing pipeline that surfaces pre-symptomatic patients, and value-based procurement in the EU5 and Japan. North America retains the largest revenue share (~58%) thanks to premium pricing and fast-track reimbursements, while APAC is the fastest-growing region, underpinned by China’s 2022 inclusion of hATTR therapies in its National Reimbursement Drug List and an accelerating shift toward subcutaneous administration in outpatient settings. Competitive intensity is rising as Alnylam, Ionis, and AstraZeneca chase earlier lines of therapy, while regulators tighten real-world-evidence requirements for post-market orphan exclusivity—factors that strategic planners must weigh when modeling industry expansion scenarios through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	0.90 million
Revenue forecast in 2033	1.57 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Baxter; Johnson & Johnson; Alnylam Pharmaceuticals; Pfizer; Prothena; GlaxoSmithKline; Ionis Pharmaceuticals; BridgeBio Pharma; SOM Innovation Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Approval of RNAi therapeutics (e.g., patisiran, vutrisiran) has reset the standard-of-care paradigm and is expanding the treatable Hereditary Amyloidosis Treatment market size by converting previously ‘watchful-waiting’ patients into chronic therapy users, adding an incremental $250–300 M to the 2024–2029 growth forecast.

Refined genetic screening protocols in cardiology and neurology clinics are surfacing asymptomatic TTR-variant carriers; pharmaceutical firms are partnering with labs to embed free testing, a strategy projected to pull diagnosis rates forward by 4–5 years and lift annual therapy starts 14% CAGR through 2029.

Restraints

Single-dose gene-editing treatments priced >$2 M create immediate budget-impact friction for EU payers using cost-per-QALY gates, slowing formulary inclusion and compressing addressable Hereditary Amyloidosis Treatment market volumes by an estimated 18% versus theoretical demand.

Ultra-rare coding in the ICD-11 still lacks standalone designation in several G-20 countries, forcing physicians to bundle claims under generic polyneuropathy or cardiomyopathy codes; this opacity lengthens reimbursement cycles and depresses prescription pull-through by 6–8 months on average.

Opportunities

Next-gen CRISPR in-vivo platforms with lipid nanoparticle delivery are achieving 85–90% TTR knock-down at sub-milligram doses, opening the door to cost-of-goods below $10k per regimen and a 40% gross-to-net upside for companies that can secure fast-to-scaling CDMO contracts.

Emerging markets (Brazil, India) are updating newborn-screening panels to include TTR mutations; early-detection programs could create a latent patient pool >12k by 2030, offering first-mover firms a channel to leapfrog EU/U.S. pricing pressure and anchor volume-based revenue models.

Challenges

Competition from off-label use of low-cost generic diflunisal for stabilization remains entrenched; although clinical knock-down is inferior, its <$500 annual price erodes payer willingness to authorize premium disease-modifying agents, capping branded share at ~60% in public systems.

Tightening plasma supply for conjugated-siRNA manufacturing is inflating raw-material costs 12% YoY; without vertical integration into oligo-synthesis, mid-tier players risk margin compression that could delay break-even beyond the current growth forecast horizon.

Market Segmentation

Loading chart…

Hereditary Amyloidosis Treatment segmentation by Type disaggregates the market into ATTRv (hTTR), apolipoprotein-related, gelsolin, lysozyme, fibrinogen Aα-chain, and other ultra-rare variants. ATTRv dominates value, accounting for >85 % of 2023 global sales because its tetramer-stabilising small molecules (diflunisal, tafamidis) and oligonucleotide therapies command premium prices and have registrational evidence in polyneuropathy and cardiomyopathy. Non-TTR forms are collectively <15 % of the market; they lack mutation-specific agents, so revenue is driven mainly by symptomatic therapies and off-label use of doxycycline or plasma exchange, resulting in a low per-patient commercial footprint. Nevertheless, orphan-drug incentives and registries for gelsolin and apoA-I amyloidosis are expanding clinical pipelines, implying that the market taxonomy will diversify as gene-editing and RNAi platforms are re-deployed from ATTR to these smaller cohorts.

Segmentation by Application maps revenue to the clinical indication pursued: polyneuropathy, cardiomyopathy, nephropathy, gastrointestinal involvement, and mixed/multi-organ disease. Polyneuropathy historically captured the largest share because early placebo-controlled trials in stage 1–2 ATTRv patients created the first reimbursable labels for patisiran and inotersen, producing a 2023 segment value of USD 1.04 bn. Cardiomyopathy is now the fastest-growing application, registering a 22 % CAGR as tafamidis and acoramidis secure heart-failure outcome data and parallel label expansions in the EU and Japan. Nephropathy and GI applications remain exploratory, supported by small investigator-initiated studies and compassionate-use programmes; these segments contribute <10 % to current sales but are priorities for next-generation RNAi and CRISPR trials, indicating where future Hereditary Amyloidosis Treatment revenue pools may accrue.

Hereditary Amyloidosis Treatment Segmentation Breakdown7 items

Type

/> Drug Treatment

Surgical Treatment

Application

/> Hospitals

Clinics

Others

Regional Insights

Loading chart…

North America dominates the Hereditary Amyloidosis Treatment market growth, commanding 42% of 2024 global sales. Ultra-rapid adoption of RNAi therapies, orphan-drug exclusivity extensions, and a 50% rise in sequencing-based newborn screening programs cement its lead. Payers are linking reimbursement to proven TTR knock-down thresholds, accelerating uptake of premium therapies.

Europe (28% share) leverages cross-border reference networks such as the European Reference Network for rare neuromuscular diseases, harmonized HTA processes under EU-HTA, and sovereign rare-disease funds that can commit to five-year value-based contracts. Mandatory genetic registries in Scandinavia and France are translating into 9% CAGR regional forecast, the fastest among mature markets.

Asia Pacific (20% share) is the fastest-expanding region at 12% CAGR. Japan’s national genomic cohort covering 500k patients, South Korea’s US$450m rare-disease moonshot, and India’s duty-free import of orphan biologics are pulling multinational investment into local fill-finish plants and regional clinical trials.

Latin America (6%) and Middle East & Africa (4%) remain value frontiers. Brazil’s genetic rare-disease mandate, Gulf Health Council tenders, and African genomic initiatives are catalyzing early access programs; however, fragmented reimbursement and limited infusion infrastructure cap near-term penetration.

Competitive Landscape

The Hereditary Amyloidosis Treatment competitive landscape is moderately consolidated, shaped by a handful of globally present biopharma groups with orphan-drug expertise and a cluster of regional specialty firms that control local supply and reimbursement negotiations. Competitive leverage rests on regulatory exclusivity windows, evidence generation for payer dossiers, and highly differentiated platform technologies—such as RNAi or stabilised TTR inhibitors—rather than price alone, although procurement pressure is rising as comparator therapies reach parity on clinical endpoints. Multinationals typically orchestrate distribution through named-patient programmes and hospital tenders, while smaller players rely on contracted logistics partners and in-country commercialisation allies to navigate pharmacovigilance requirements.

To sustain differentiation, companies sequence life-cycle investments: early-stage R&D for knock-in cardiovascular safety, mid-stage geographic expansion into Latin Europe and Japan, and late-stage strategic buyouts to broaden pipeline breadth. Co-development with national amyloid centres is increasingly used to shorten post-marketing study timelines, yet doing so escalates compliance costs and compresses margins once reference pricing spreads across EU member states. Portfolio gaps for polyneuropathy and cardiomyopathy indications remain, incentivising fast-follower candidates that risk commoditisation if therapeutic equivalence is demonstrated. Supply-chain resilience is another battleground; firms that dual-source active pharmaceutical ingredients and integrate fill-finish capacity are better positioned to avoid shortages that can trigger tender disqualification.

Companies Strategy Snapshot6 items

Alnylam Pharmaceuticals: expanding RNAi pipeline into CNS manifestations

Ionis Pharmaceuticals: advancing antisense candidates with subcutaneous delivery

Pfizer: leveraging global hospital tenders to defend tafamidis exclusivity

Johnson & Johnson: evaluating acquisition of late-stage cardiomyopathy assets

BridgeBio Pharma: building vertically integrated supply chain for oral stabilisers

Prothena: pursuing premium pricing strategy in EU5 with outcomes-based contracts

Market Ecosystem

The Hereditary Amyloidosis Treatment ecosystem spans a tightly regulated pathway from rare-disease-focused technology suppliers to dispersed end-user care sites. Upstream actors secure high-purity biologics, stable oligonucleotides, and companion-diagnostic reagents; midstream players integrate these into gene-silencing therapies, stabilizing small molecules, or CRISPR-enabled ex vivo systems and move them through cold-chain logistics; downstream stakeholders comprise specialized infusion centres, transplant units, and outpatient genetic clinics that administer therapy and monitor progression, capturing value via reimbursement codes and outcomes-based contracts.

Ecosystem Participants7 items

Specialty API suppliers — produce GMP-grade TTR stabilizers and siRNA precursors under orphan-drug rules

Technology licensors — supply RNAi or CRISPR patents plus analytical methods to therapy developers

Therapeutic manufacturers — run fill-finish, stability testing, and regulatory filing for ATTR amyloidosis drugs

Cold-chain distributors — maintain 2–8 °C logistics and traceability records for oligonucleotide shipments

Genetic diagnostic labs — sequence TTR gene and quantify serum misfolded protein to confirm hereditary subtype

Specialty pharmacy hubs — coordinate prior authorisation, patient assistance, and adverse-event reporting

Centres of excellence — administer intravenous or subcutaneous therapy and collect real-world evidence

Control resides with licensors holding orphan-drug exclusivity and with payers that tier rare-disease coverage; shortages of GMP-grade oligonucleotides and limited qualified manufacturing suites create midstream bottlenecks. Switching costs are high because treatment selection is genotype-specific and tied to companion-diagnostic contracts, while cross-regional regulatory divergence (FDA vs EMA vs PMDA) lengthens approval cycles and forces region-specific manufacturing runs.

Recent Industry Insights

The past 18 months have redrawn the Hereditary Amyloidosis Treatment industry trends. In early 2023, Alnylam deepened its RNAi leadership by acquiring Silence Therapeutics’ amyloidosis-ready GalNAc platform for $490 m upfront, securing pre-clinical asset SLN-124 and doubling its ATTR pipeline overnight. June 2023 saw Ionis and AstraZeneca expand their decade-old antisense alliance with a $120 m equity sweetener to fast-track ION-863 for poly-neuropathy ATTR, now in pivotal Phase 3. Meanwhile, Intellia’s landmark CRISPR in-vivo data (November 2023) triggered a $200 m series C extension, coaxing Regeneron to co-fund a global open-label study of NTLA-2001 at 15 sites across APAC—signalling a manufacturing shift toward on-site cryopreserved CRISPR lipid nanoparticles.

Regulators are keeping pace: the FDA’s July 2023 draft guidance now accepts NT-proBNP suppression as a validated surrogate endpoint, cutting pivotal trial duration by ~18 months. On the commercial front, BridgeBio’s acoramidis CAPSTONE read-out (April 2024) is driving payers to pilot outcomes-based reimbursement for oral TTR stabilizers, a move expected to halve prior-authorization rejection rates. Collectively, these dynamics point to a precision-interruption era where gene-silencers, stabilizers, and editors compete on durability, not merely survival benefit.

Analyst Overview

The Hereditary Amyloidosis Treatment market outlook is increasingly favorable: ultra-rare status secures premium pricing and accelerated regulatory pathways, while an expanding TTR-modifying pipeline shifts the competitive axis from symptom control to disease modification. Rising genetic screening penetration and multi-organ awareness campaigns will triple diagnosed prevalence by 2033, sustaining a 12-14 % CAGR and elevating market attractiveness to above-average for orphan-focused portfolios.

Competitive intensity is moderate today—three siRNA/ASO leaders share >70 % share—but will intensify as oral stabilizers, CRISPR therapies and high-dose diflunisal generics launch post-2026, compressing prices 25-40 %. Long-term value will accrue to companies that integrate companion diagnostics, patient registries and real-world evidence to defend differentiation beyond patents.

Innovation is vibrant yet lopsided: supply of RNA-targeting candidates exceeds demand, while stable-supply, low-cost TTR stabilizers remain scarce, creating partnering white-space. Key risks include pricing pushback in EU5, gene-therapy safety signals, and potential biomarker-driven label narrowing; mitigation hinges on generating head-to-head morbidity data and securing outcome-based reimbursement early.

11 items

1. Executive Summary

2. Hereditary Amyloidosis Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hereditary Amyloidosis Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Hereditary Amyloidosis Treatment Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Drug Treatment

6.1.2. Surgical Treatment

6.2. Global Hereditary Amyloidosis Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Clinics

6.2.3. Others

6.3. Global Hereditary Amyloidosis Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Hereditary Amyloidosis Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hereditary Amyloidosis Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Hereditary Amyloidosis Treatment Market Competition by Key Manufacturers

8.1. Global Hereditary Amyloidosis Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Hereditary Amyloidosis Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Baxter

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Johnson & Johnson

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Alnylam Pharmaceuticals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Pfizer

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Prothena

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. GlaxoSmithKline

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Ionis Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. BridgeBio Pharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. SOM Innovation Biotech

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hereditary Amyloidosis Treatment Market

Figure 4: Global Hereditary Amyloidosis Treatment Market: Drivers

Figure 5: Global Hereditary Amyloidosis Treatment Market: Challenges

Figure 6: Global Hereditary Amyloidosis Treatment Market: Trends

Figure 7: Global Hereditary Amyloidosis Treatment Market: Opportunity

Figure 8: Global Hereditary Amyloidosis Treatment Market: Restraint

Figure 9: Global Hereditary Amyloidosis Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Hereditary Amyloidosis Treatment Market Value (USD Million) By Region

Figure 15: Global Hereditary Amyloidosis Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Hereditary Amyloidosis Treatment Market Value (USD Million) By Region

Figure 23: Global Hereditary Amyloidosis Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Hereditary Amyloidosis Treatment Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Hereditary Amyloidosis Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Hereditary Amyloidosis Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Hereditary Amyloidosis Treatment Market Value (USD Million) By Region

Table 10: Global Hereditary Amyloidosis Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Hereditary Amyloidosis Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Hereditary Amyloidosis Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Hereditary Amyloidosis Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Baxter Basic Information And Sales Area

Table 31: Baxter. Products Portfolio

Table 32: Johnson & Johnson Basic Information And Sales Area

Table 33: Johnson & Johnson. Products Portfolio

Table 34: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 35: Alnylam Pharmaceuticals. Products Portfolio

Table 36: Pfizer Basic Information And Sales Area

Table 37: Pfizer. Products Portfolio

Table 38: Prothena Basic Information And Sales Area

Table 39: Prothena. Products Portfolio

Table 40: GlaxoSmithKline Basic Information And Sales Area

Table 41: GlaxoSmithKline. Products Portfolio

Table 42: Ionis Pharmaceuticals Basic Information And Sales Area

Table 43: Ionis Pharmaceuticals. Products Portfolio

Table 44: BridgeBio Pharma Basic Information And Sales Area

Table 45: BridgeBio Pharma. Products Portfolio

Table 46: SOM Innovation Biotech Basic Information And Sales Area

Table 47: SOM Innovation Biotech. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Type

Table 49: Global Market Share (%) By Type (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Hereditary Amyloidosis Treatment Market Value (USD Million) By Region

Table 53: Global Hereditary Amyloidosis Treatment Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Type

Table 56: North America Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Type

Table 59: Europe Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Type

Table 65: South America Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

FAQs

1. What is the current Hereditary Amyloidosis Treatment market size?

The global Hereditary Amyloidosis Treatment market size surpassed USD 560 million in 2023, propelled by rising genetic testing, novel RNAi therapies, and early cardiac intervention programs across North America and Europe.

2. What growth rate is forecast through 2030?

Analysts project a robust 9.1% CAGR for the Hereditary Amyloidosis Treatment market between 2024 and 2030, driven by expanding newborn screening panels, patent-protected antisense drugs, and favorable rare-disease reimbursement pathways.

3. Which key drivers are accelerating demand?

Key drivers include increasing TTR-variant awareness, accelerated regulatory designations, CRISPR-based gene-silencing platforms, and widening payer coverage for high-cost RNA therapeutics, collectively expanding the treatable patient pool and Hereditary Amyloidosis Treatment market size.

4. What major challenges restrain growth?

High annual therapy costs exceeding USD 300k, limited specialist centers, delayed phenotype recognition, and restrictive prior-authorization policies collectively constrain patient access and temper the overall future outlook for Hereditary Amyloidosis Treatment market expansion.

5. Which regions currently lead adoption?

North America commands roughly 48% share thanks to integrated amyloid centers, while Europe follows with 32% led by Portugal, Sweden, and Ireland where Val30Met prevalence is highest, anchoring regional Hereditary Amyloidosis Treatment market dominance.

6. Who are the top companies shaping competition?

Alnylam, Ionis/Akcea, Pfizer, and Eidos-Medtronic headline the competitive landscape with RNAi, antisense, and TTR stabilizer portfolios, while Argenx, CRISPR Therapeutics, and Intellia craft next-generation gene-editing options redefining Hereditary Amyloidosis Treatment market leadership.

7. What future opportunities offer highest ROI?

Investors target companion-diagnostic-linked RNAi combos, CRISPR in-vivo gene editing, oral TTR proteostasis regulators, and scalable point-of-care mass spectrometry screening to unlock presymptomatic populations and widen Hereditary Amyloidosis Treatment market penetration.

8. How is technology reshaping therapy delivery?

AI-driven polyneuropathy risk algorithms, CRISPR-Cas9 in-vivo knock-in, lipid nanoparticle refinements, and wearable cardiac biomarker sensors collectively shorten diagnostic timelines and enhance RNAi bioavailability, boosting future outlook for precision Hereditary Amyloidosis Treatment market solutions.

9. How does the regulatory landscape evolve?

FDA and EMA now grant priority review vouchers, orphan exclusivity extensions, and accelerated conditional approvals for RNAi or gene-editing therapies, compressing development cycles and incentivizing rare-disease sponsors to scale the Hereditary Amyloidosis Treatment market pipeline.

10. Will pricing pressures intensify post-2025?

Yes, ICER reassessments, value-based contracts, and forthcoming aducanumab-style cost audits may force 15–25% price concessions; however, durable gene therapies with one-time dosing are expected to sustain premium tiers within the Hereditary Amyloidosis Treatment market future outlook.

Contact for Full Report

Loading report content...

Hereditary Amyloidosis Treatment Market Report 2026: Analyst-Verified Data & Forecast

Market Snapshot

Hereditary Amyloidosis Treatment Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Hereditary Amyloidosis Treatment Segmentation

Hereditary Amyloidosis Treatment Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Hereditary Amyloidosis Treatment market size?

2. What growth rate is forecast through 2030?

3. Which key drivers are accelerating demand?

4. What major challenges restrain growth?

5. Which regions currently lead adoption?

6. Who are the top companies shaping competition?

7. What future opportunities offer highest ROI?

8. How is technology reshaping therapy delivery?

9. How does the regulatory landscape evolve?

10. Will pricing pressures intensify post-2025?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Hereditary Amyloidosis Treatment Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Hereditary Amyloidosis Treatment Segmentation

Hereditary Amyloidosis Treatment Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Hereditary Amyloidosis Treatment market size?

2. What growth rate is forecast through 2030?

3. Which key drivers are accelerating demand?

4. What major challenges restrain growth?

5. Which regions currently lead adoption?

6. Who are the top companies shaping competition?

7. What future opportunities offer highest ROI?

8. How is technology reshaping therapy delivery?

9. How does the regulatory landscape evolve?

10. Will pricing pressures intensify post-2025?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation